Q2 EPS Forecast for MiNK Therapeutics Increased by Analyst

MiNK Therapeutics, Inc. (NASDAQ:INKT) – Research analysts at HC Wainwright lifted their Q2 2026 earnings estimates for shares of MiNK Therapeutics in a note issued to investors on Monday, May 18th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($0.60) per share for the quarter, up from their prior estimate of ($0.87). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($3.27) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.46) EPS, FY2027 earnings at ($2.39) EPS, FY2028 earnings at ($3.49) EPS, FY2029 earnings at ($2.07) EPS and FY2030 earnings at $0.05 EPS.

Other analysts have also issued research reports about the stock. Wall Street Zen raised shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings lowered shares of MiNK Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, MiNK Therapeutics has a consensus rating of “Hold” and an average target price of $35.00.

MiNK Therapeutics Stock Performance

INKT opened at $10.35 on Wednesday. The company has a fifty day moving average price of $10.99 and a two-hundred day moving average price of $11.53. MiNK Therapeutics has a 52 week low of $6.65 and a 52 week high of $76.00. The firm has a market capitalization of $51.54 million, a PE ratio of -3.64 and a beta of 0.47.

MiNK Therapeutics (NASDAQ:INKT) last released its earnings results on Friday, May 15th. The company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.20.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC grew its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent quarter. Institutional investors and hedge funds own 2.87% of the company’s stock.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.